Drugs / IBI188
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT04861948 | May 2021 → Jul 2022 | lung adenocarcinoma, osteosarcoma | Innovent Biologics (Suzhou) Co. Ltd. | Terminated | No outcome recorded |
| Phase 1 | NCT04485065 | Sep 2020 → Dec 2023 | myelodysplastic syndrome | Innovent Biologics (Suzhou) Co. Ltd. | Suspended | No outcome recorded |
| Phase 1 | NCT04511975 | Aug 2020 → Oct 2021 | myelodysplastic syndrome | Innovent Biologics (Suzhou) Co. Ltd. | Suspended | No outcome recorded |
| Phase 1 | NCT03763149 | Feb 2019 → Mar 2021 | cancer | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03717103 | Jan 2019 → Feb 2022 | cancer | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04485052 | Sep 2020 → Jun 2024 | acute myeloid leukemia | Innovent Biologics (Suzhou) Co. Ltd. | Suspended | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI188 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04511975 ↗ |
| Known as | LETAPLIMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594553 ↗ |
| Modality | Monoclonal antibody | “Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188)” NCT03717103 ↗ |
| Route | Intravenous | “0.1 mg/kg IV QW” NCT03717103 ↗ |
| Target | CD47 | “Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody” NCT03717103 ↗ |